Abstract:Objective Based on the Food and Drug Administration Adverse Event Reporting System (FAERS) database in the United States. The aim of this study was to explore and study the adverse events (ADE) of polymyxin B, providing reference for rational clinical medication.Methods Retrieve and download FAERS database data from the first quarter of 2004 to the fourth quarter of 2023, Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR) and the Medicines And Healthcare Products Regulatory Agency (MHRA) were used to analyze the ADE reports of polymyxin B.Results A total of 294 ADE samples were extracted with polymyxin B as the primary suspected drug. After screening, 21 effective signals were excavated and 128 ADE reports were excavated, involving 12 system organ class (SOC). The top three reported cases were renal and urinary disorders, nervous system disorders, injury, poisoning and procedural complications. The strongest ADE signals were skin hyperpigmentation. It was also found that such ADE as skin hyperpigmentation, nosocomial infection, rhabdomyolysis, hypokalaemia and septic shock, etc., were not mentioned in the manual.Conclusion When using polymyxin B, attention should be paid to ADE such as renal and urinary disorders, nervous system disorders, injury, poisoning and procedural complications, infections and infestations, and timely prevention and control measures should be taken to reduce the risk of clinical use.